EMJ Oncology 9 [Supplement 3] . 2021

In this issue

DURING a satellite symposium at the virtual 17th St Gallen International Breast Cancer Conference 2021, Dr Aleix Prat and Dr Giuseppe Curigliano discussed reimagining treatment of HR+, HER2- early breast cancer (EBC).

They covered important topics such as recurrence risk, the rationale for CDK4/6 inhibitors in EBC and who may benefit from such treatment, and what the future might look like in EBC.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?